Despite limitations in cohort heterogeneity, this study positions PSMB9 as a pivotal orchestrator of tumor immune landscapes, highlighting its potential as a biomarker and therapeutic target to advance precision immunotherapy. The gene discussed is PSMB9; the disease is neoplasm.